Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trialFei Ma, Binghe Xu, Quchang Ouyang et al.|BMJ|2023Cited by 82
LEONARDA-2: Lerociclib plus letrozole versus placebo plus letrozole in HR+/HER2- advanced or metastatic breast cancer.Xichun Hu, Biyun Wang, Shusen Wang et al.|Journal of Clinical Oncology|2024Cited by 1